Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors
Public ClinicalTrials.gov record NCT03509012. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase I Multicenter Study of Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors (CLOVER)
Study identification
- NCT ID
- NCT03509012
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- AstraZeneca
- Industry
- Enrollment
- 105 participants
Conditions and interventions
Conditions
Interventions
- Durvalumab Drug
- Tremelimumab Drug
- Cisplatin (dose level 4) Drug
- Cisplatin (dose level 3) Drug
- Carboplatin (dose level 1) Drug
- Carboplatin (dose level 2) Drug
- Etoposide (dose level 1) Drug
- Etoposide (dose level 2) Drug
- Paclitaxel Drug
- Pemetrexed Drug
- External beam radiation (dose level 1) Radiation
- External beam radiation (dose level 2) Radiation
- External beam radiation (hyperfractionated) Radiation
- Cisplatin (dose level 1) Drug
- Cisplatin (dose level 2) Drug
- External beam radiation (standard) Radiation
Drug · Radiation
Eligibility (public fields only)
- Age range
- 18 Years to 110 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 1, 2018
- Primary completion
- Dec 30, 2020
- Completion
- Jan 7, 2025
- Last update posted
- Jan 13, 2025
2018 – 2025
United States locations
- U.S. sites
- 3
- U.S. states
- 3
- U.S. cities
- 3
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Tucson | Arizona | 85719 | — |
| Research Site | Aurora | Colorado | 80045 | — |
| Research Site | Houston | Texas | 77090 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 13 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03509012, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 13, 2025 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03509012 live on ClinicalTrials.gov.